Fulcrum Therapeutics (FULC) Expected to Announce Quarterly Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC) is projected to announce its Q1 2026 results before the market opens on Monday, April 27th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, April 27, 2026 at 8:00 AM ET.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). On average, analysts expect Fulcrum Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulcrum Therapeutics Stock Performance

Shares of FULC opened at $7.84 on Friday. The firm’s 50-day simple moving average is $8.12 and its two-hundred day simple moving average is $9.56. The stock has a market cap of $522.14 million, a PE ratio of -6.64 and a beta of 3.27. Fulcrum Therapeutics has a fifty-two week low of $3.38 and a fifty-two week high of $15.74.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. grew its stake in shares of Fulcrum Therapeutics by 236.8% in the 4th quarter. Invesco Ltd. now owns 417,189 shares of the company’s stock worth $4,718,000 after buying an additional 293,317 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth $586,000. Ikarian Capital LLC grew its stake in shares of Fulcrum Therapeutics by 6.7% in the 4th quarter. Ikarian Capital LLC now owns 1,375,472 shares of the company’s stock worth $15,557,000 after buying an additional 86,247 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth $10,744,000. Finally, Virtus Investment Advisers LLC purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth $231,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on FULC. JPMorgan Chase & Co. began coverage on shares of Fulcrum Therapeutics in a research report on Monday, January 12th. They issued an “overweight” rating and a $20.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday. Wall Street Zen cut shares of Fulcrum Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 12th. Truist Financial set a $17.00 target price on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.00.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.